Bibliography
- Stoll BJ, Hansen NI, Bell EF, et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network 3. Pediatrics 2010;126:443-56
- Shah PS, Kaufman DA. Antistaphylococcal immunoglobulins to prevent staphylococcal infection in very low birth weight infants. Cochrane Database Syst Rev 2009(2):CD006449
- Benjamin DK, Schelonka R, White R, et al. A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin. J Perinatol 2006;26:290-5
- DeJonge M, Burchfield D, Bloom B, et al. Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants 1. J Pediatr 2007;151:260-5
- Fanaroff AA, Korones SB, Wright LL, et al. A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. National institute of child health and human development neonatal research network. N Engl J Med 1994;330:1107-13
- Weisman LE, Schuman RF, Lukomska E, et al. Effectiveness and pharmacokinetics of an anti-lipoteichoic acid humanized mouse chimeric monoclonal antibody [abstract]. Available from: http://www abstracts2view com/pasall/ 2001
- Weisman LE, Fischer GW, Thackray HM, et al. Safety and pharmacokinetics of a chimerized anti-lipoteichoic acid monoclonal antibody in healthy adults. Int Immunopharmacol 2009;9:639-44
- Theilacker C, Kropec A, Hammer F, et al. Protection against Staphylococcus aureus by antibody to the polyglycerolphosphate backbone of heterologous lipoteichoic acid. J Infect Dis 2012;205:1076-85
- Weisman LE. Coagulase-negative staphylococcal disease: emerging therapies for the neonatal and pediatric patient 2. Curr Opin Infect Dis 2004;17:237-41
- Weisman LE, Thackray HM, Steinhorn RH, et al. A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis. Pediatrics 2011;128:271-9
- Weisman LE, Thackray HM, Garcia-Prats JA, et al. Phase I/II double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates. Antimicrob Agents Chemother 2009;53:2879-86
- Biosynexus. Safety and efficacy of pagibaximab injection in very low birth weight neonates for prevention of staphylococcal sepsis. Available from: http://www clinicaltrials gov/ct2/show/NCT00646399?term=Pagibaximab&rank=1 2011
- Eibl MM, Wolf HM, Furnkranz H, et al. Prevention of necrotizing enterocolitis in low-birth-weight infants by IgA-IgG feeding. N Engl J Med 1988;319:1-7
- Eibl MM, Wolf HM, Furnkranz H, et al. Prophylaxis of necrotizing enterocolitis by oral IgA-IgG: review of a clinical study in low birth weight infants and discussion of the pathogenic role of infection. J Clin Immunol 1990;10:72S-7S
- Carr R. The role of colony stimulating factors and immunoglobulin in the prevention and treatment of neonatal infection. Arch Dis Child Fetal Neonatal Ed 2013;98:F192-4
- Reichmann NT, Picarra CC, Monteiro JM, et al. Differential localization of LTA synthesis proteins and their interaction with the cell division machinery in Staphylococcus aureus. Mol Microbiol 2014;92:273-86
- Power Coombs MR, Kronforst K, Levy O. Neonatal host defense against Staphylococcal infections. Clin Dev Immunol 2013;2013:826303
- Manzoni P, Rinaldi M, Cattani S, et al. Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial. JAMA 2009;302:1421-8
- Brocklehurst P, Farrell B, King A, et al. Treatment of neonatal sepsis with intravenous immune globulin 2. N Engl J Med 2011;365:1201-11